Skip to main content
NSPR
NASDAQ Industrial Applications And Services

InspireMD Q3 Revenue Falls 11.1% to $2.24M; Cash Drops to $19.2M Ahead of TCAR Launch

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.65
Mkt Cap
$35.983M
52W Low
$0.425
52W High
$2.22
52W Position info
53% above low
Off High info
71% below high
Rel. Volume info
4.9× avg
Market data snapshot near publication time

NSPR sits 53% above its 52-week low of $0.425 on elevated volume (4.9× avg).

Summary

InspireMD's Q3 revenue fell 11.1% to $2.24M as U.S. sales dried up after the recall, and cash fell to $19.2M from $54.2M at year-end. The FDA's TCAR approval is the offset, with U.S. sales expected to start in Q4 2026.


Key Events · Earnings and Guidance · NSPR

  • Q3 Revenue Falls 11.1% on Recall

    Total revenue was $2,242,000 versus $2,523,000 a year ago. U.S. revenue collapsed to $32,000 from $497,000 after the May 2026 CGuard Prime for CAS delivery-system recall, while international revenue rose 9.1% to $2,210,000.

  • Gross Margin Collapses to 10.7%

    Gross profit was $240,000, or 10.7% of revenue, versus $864,000, or 34.2%, a year earlier, driven by the recall and a shift in international mix to lower-average-selling-price countries.

  • Cash Falls to $19.2M From $54.2M

    Cash, cash equivalents and marketable securities totaled $19,246,000 at September 30, 2026, versus $54,211,000 at December 31, 2025, against a nine-month net loss of $37,775,000.

  • FDA TCAR Approval Sets Up Q4 Launch

    The FDA approved CGuard Prime for TCAR procedures, which the company says adds over 35,000 procedures annually to its addressable market; U.S. sales are expected to commence promptly in Q4 2026.


Analysis · NSPR · Industrial Applications And Services

The cash position is the real story here. Revenue fell to $2,242,000 from $2,523,000 a year ago, as U.S. sales collapsed to $32,000 from $497,000 following the May 2026 recall of the CGuard Prime for CAS delivery system. Gross margin fell to 10.7% from 34.2%, and the net loss was $9,762,000. Cash and marketable securities stood at $19,246,000 at September 30 versus $54,211,000 at December 31, 2025, against a nine-month net loss of $37,775,000. That burn rate means the company will need to raise money again, and it already has a $75M ATM program in place. The offset is the November 12 FDA approval of CGuard Prime for TCAR, which the company says expands the addressable market by over 35,000 procedures annually and should start generating U.S. sales in Q4 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NSPR was trading at $0.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36M. The 52-week trading range was $0.43 to $2.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NSPR - Latest Insights

NSPR
Nov 12, 2026, 4:15 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.730
Real-time Price: $0.6501 info
Change: -$0.0799 (-11%) info
Market Cap: $35.983M info
NSPR
Nov 12, 2026, 4:03 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9087
Real-time Price: $0.6501 info
Change: -$0.2586 (-28%) info
Market Cap: $35.983M info
NSPR
Nov 12, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.774
Real-time Price: $0.6501 info
Change: -$0.1239 (-16%) info
Market Cap: $35.983M info
NSPR
Sep 21, 2026, 9:12 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.6501 info
Change: -$0.1199 (-16%) info
Market Cap: $35.983M info
NSPR
Sep 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.770
Real-time Price: $0.6501 info
Change: -$0.1199 (-16%) info
Market Cap: $35.983M info